Description du projet
Un outil de diagnostic pour détecter les premiers signes de la maladie d’Alzheimer
La maladie d’Alzheimer (MA) n’est pas guérissable aux stades finaux, mais une détection et un traitement précoces pourraient avoir des apports thérapeutiques et sociétaux importants. Un traitement commencé dès les premiers stades pourrait ralentir, voire même guérir la MA, ce qui réduirait considérablement les coûts des soins de santé. La société norvégienne Pre Diagnostics travaille à la création d’un outil de diagnostic permettant d’identifier les patients à un stade très précoce, avant que la MA ne devienne visible. Cet outil précis et abordable de détection de biomarqueurs sanguins analysera directement le métabolisme cérébral des patients et détectera une clairance réduite de la bêta-amyloïde, qui représente le premier signal dans la pathologie de la MA. Le projet VERDAD, financé par l’UE, apportera son soutien aux dernières étapes réglementaires du développement du nouvel outil et le préparera pour le marché.
Objectif
Alzheimer’s Disease (AD) poses an unbearable impact in patients’ life, through progressive loss of cognitive capacities and overall quality of life. In Europe alone, there is currently a €280 bn yearly expenditure related to AD and ~10% of the population above 65 years old is currently affected by the disease, a figure that is expected to triple in the immediate future.
No treatment alternatives are available for AD patients with diagnosed disease and the existing diagnostic tools are very time consuming and expensive (6 months / 10.000 EUR). While AD is not curable at final stages of disease, detection at early stages offer several treatment alternatives for example through counseling and/or dietary interventions.
Detection and treatment of AD in its initial stages could provide major therapeutic and societal benefits. Treatment strategies at early stages could either slow down or even cure AD which would dramatically reduce the health care costs.
PreDiagnostics will exploit and transfer research knowledge developed by its founders to a commercial setting and provide a diagnostic tool to identify patients at early stages before disease is evident. Through the VERDAD project, PreDiagnostics will finalize the final regulatory steps and introduce into the market a novel, accurate and cost-effective blood biomarker detection tool. This tool directly analyses the patients’ brain metabolism and detects reduced clearance of beta-amyloid which is the first step in AD pathology.
The VERDAD project will allow for market introduction of a disruptive diagnostic test to identify AD decades before clinical signs are visible. This will facilitate early disease diagnosis and implementation of prevention strategies in likely patients. We have developed necessary collaborations to roll-out our diagnostic tool which will lead to major costs saving for the Health Care sector, generate new employment opportunities and in unlock a revenue stream of over €1.5bn 10-years post-Project.
Champ scientifique
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
0382 Oslo
Norvège
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.